 Pfizer Inc. explored a potential tax-lowering takeover of rival Actavis PLC in recent weeks, but talks between the two pharmaceutical companies have ended, according to a person familiar with the matter.. New York-based Pfizer approached Actavis proposing a cash-and-stock tie-up, according to the person. The talks ended last week after Actavis decided against a deal, the person said. It is unclear why. Actavis has a market value of about $60 billion.